NEAL R. GROSS & CO., INC.

RPTS MICHON

HIF307140

EXAMINING LEGISLATION TO IMPROVE MEDICARE

AND MEDICAID

TUESDAY, NOVEMBER 3, 2015

House of Representatives,

Subcommittee on Health,

Committee on Energy and Commerce,

Washington, D.C.

The subcommittee met, pursuant to call, at 10:15 a.m., in Room 2322 Rayburn House Office Building, Hon. Joe Pitts [chairman of the subcommittee] presiding.

Members present: Representatives Pitts, Guthrie, Shimkus, Blackburn, Lance, Griffith, Bilirakis, Long, Bucshon, Brooks, Collins, Green, Castor, Sarbanes, Schrader, Kennedy, and Pallone (ex officio).

Also present: Representative Loebsack.

Staff present: Clay Alspach; Chief Counsel, Health; Rebecca Card, Staff Assistant; Karen Christian, General Counsel; Graham Pittman, Legislative Clerk; Michelle Rosenberg, GAO Detailee, Health; Chris Sarley, Policy Coordinator, Environment and Economy; Heidi Stirrup, Health Policy Coordinator; Josh Trent, Professional Staff Member, Health; Christine Brennan, Press Secretary; Jeff Carroll, Staff Director; Tiffany Guarascio, Deputy Staff Director and Chief Health Advisor; Rachel Pryor, Health Policy Advisor; Samantha Satchell, Policy Analyst; and Arielle Woronoff, Health Counsel.

1	Mr. Pitts. Okay. I will ask our guests to please take their
2	seats and the subcommittee will come to order. The chair will
3	recognize himself for an opening statement.
4	Today's hearing will examine five bipartisan legislative
5	bills designed to make common sense improvements to the Medicare
6	and Medicaid programs.
7	First, the committee is happy to have with us one of our own
8	colleagues, Rep. Lynn Jenkins from Kansas. Rep. Jenkins will be
9	testifying on our first panel about a bill she is sponsoring, H.R.
10	2878.
11	This bill would simply prohibit Medicare contractors from
12	enforcing supervision requirements for outpatient therapeutic
13	services and critical access in small rural hospitals for another
14	year.
15	The Senate companion to this bill was approved by the Senate
16	Finance Committee in June so we are pleased to be able to review
17	this bill today.
18	On our second panel, we will hear from representatives of
19	the Government Accountability Office, GAO, and the Medicaid and
20	CHIP Payment and Access Commission, MACPAC.
21	GAO and MACPAC will help us in our review of four bipartisan
22	bills to improve Medicaid. The first Medicaid bill is an updated
23	version of H.R. 1362, the Medicaid Reports Act, by Vice Chairman

1	Guthrie.
2	This bill seeks to address GAO and MACPAC findings that the
3	Centers for Medicare and Medicaid Services, CMS, does not collect
4	accurate and complete data from all states on the various sources
5	of funds to finance the nonfederal share.
6	This bill requires states to submit a report at least once
7	a year on sources of funds used to finance the nonfederal share
8	of expenditures in the Medicaid program.
9	This issue is important policy because state financing
10	approaches affect Medicaid payment methodologies and payment
11	amounts, which may affect enrollees' access to services.
12	The next Medicaid bill is H.R. 2151, sponsored by our
13	colleague, Rep. Chris Collins, the Improving Oversight and
14	Accountability in Medicaid Non-DSH Supplemental Payments Act,
15	would improve the calculation, oversight and accountability of
16	non-DSH supplemental payments under the Medicaid program.
17	This is important because GAO founds gaps in federal
18	oversight of high-risk supplemental payments including a lack of
19	information on the providers receiving them, inaccurate payment
20	calculation method and a lack of assurances the payments were used
21	for Medicaid purposes.
22	In 2014, MACPAC recommended that the HHS collect and make
23	publically available provider label non-DSH supplemental payment

1	data in a standard format that enables analysis.
2	Thirdly, the updated version of H.R. 1361, Medicaid Home
3	Improvement Act, sponsored by Rep. Guthrie, would establish a
4	federal cap on the home equity allowance consistent with the
5	current federal default of \$552,000.
6	This bill would preserve existing beneficiary protections
7	but help protect taxpayers by updating the limit of allowable
8	equity interest a beneficiary can have in their home.
9	This is a common sense step to prevent cost shifting from
10	the private to the public sector. And finally, the Quality Care
11	for Moms and Babies Act, sponsored by Reps. Engel and Stivers,
12	seeks to improve the quality, health outcomes and value of
13	maternity care under the Medicaid and CHIP programs by developing
14	maternity care quality measures.
15	This bill would authorize the appropriations of \$16 million
16	for HHS to identify and publish quality measures for maternal and
17	infant health.
18	Together, these five bills continue the commitment that this
19	Congress has to strengthen the Medicare and Medicaid programs to
20	help sustain these important safety net programs for those most
21	relying on them.
22	I want to thank all of our witnesses for agreeing to testify
23	today and I yield back and now recognize the ranking member of

the subcommittee, Mr. Green, 5 minutes for his opening statement. 1 2 Mr. Green. Thank you, Mr. Chairman, and welcome our 3 colleague from Kansas. Thank you for being here today. We are here to examine five legislative proposals. 4 5 impacts the Medicare Part B program and the other affect the 6 Medicaid program. As we know, the Medicaid program has served 7 as a critical safety net for the American public since its creation 8 on 1965, 50 years ago this year. 9 Today, over 70 million low-income Americans rely on Medicaid for comprehensive affordable health care. Medicaid covers more 10 than one in three children, pays for nearly half of all births 11 12 and accounts for more than 40 percent of the nation's total cost 13 for long-term care. One in seven Medicare beneficiaries is also a Medicaid 14 15 beneficiary -- dual eligible. The Quality Care for Moms and 16 Babies Act, the discussion and draft put forth by Reps. Engel and 17 Stivers, will improve health outcomes for women and children who 18 depend on Medicaid. This legislation will authorize funding for HHS to develop 19 20 quality measures for maternal and infant health and award grants 21 related to care quality and I support this important legislation. 2.2 I am concerned about the other legislation we are considering 23 such as the Medicaid REPORTS Act and proposals requiring

additional auditing on states that are overly burdensome,

2 prescriptive, and likely intended to chip away at the Medicaid 3 program. Additional transparency on Medicaid payments is a goal we 4 5 My priority is always including ensuring Medicaid 6 beneficiaries have access to the care that they need by supporting 7 providers that serve beneficiaries who otherwise have nowhere 8 else to go for the necessary care. 9 However, these bills as structured will not achieve our goal of fully understanding Medicaid payments and whether these 10 11 payments are adequate to quarantee equal access for beneficiaries within the Medicaid program. 12 13 My state of Texas use supplemental and Medicaid DSH payments 14 in a unique way. These sources of funding are an incredible and 15 important revenue stream for hospitals and providers that serve 16 a large portion of Medicaid beneficiaries and the uninsured. 17 For example, in Texas supplemental payments are used for 18 DSRIP and I want to make sure we maintain the flexibility so CMS 19 and states can deliver each Medicaid program the best way for its 20 unique patient base. 21 Providers in a Medicaid program must be paid a fair rate. 2.2 Given the complexities and the 56 distinct Medicaid programs, 23 there is a nuanced way to address these issues.

1	The question you need to ask is its full payment that a
2	provider receives for treating a Medicaid enrollee fair and
3	sufficient to ensure equal access.
4	Unfortunately, legislation like Medicaid Reports Act, H.R.
5	2125, won't get us the information we need to see the full picture
6	and it may actually put more burdens on the states. They are not
7	in line with the actions CMS has taken to improve in the area and
8	I look forward to learning more about this complex issue.
9	Reforms done for the right reasons and nuance in an
10	intelligence way can truly improve how CMS ensures that payments
11	to Medicaid providers are sufficient and enforce equal access to
12	Medicaid beneficiaries.
13	Such proposals should be a priority for our committee and
14	I look forward to a comprehensive discussion on ways we can improve
15	transparency, strengthen coverage and expand access to providers
16	and increase the quality of health care.
17	And Mr. Chairman, I will yield the remainder of my time to
18	my colleague from Iowa, Dave Loebsack.
19	Mr. Loebsack. I thank Mr. Green for yielding.
20	I also want to thank my colleague, Congresswoman Jenkins,
21	for testifying here today on our bill. I am happy to be the lead
22	Democratic cosponsor of H.R. 2878.
23	It has been a pleasure to work with her on this issue. As

1	a native Kansan, she truly understands the needs of rural
2	Americans and I thank her for her bipartisan work on the bill.
3	Basically, what 2878 would do is suspend the physician direct
4	supervision requirement for outpatient therapeutic services
5	furnished at critical access hospitals and small rural hospitals
6	until January of 2016.
7	I often visit critical access hospitals in my district.
8	There are many, given that I represent rural Iowa, and the
9	number-one concern I have heard about recently was this direct
10	supervision issue.
11	In 2009, CMS issued a rule that mandated direct supervision
12	for all outpatient therapeutic services at these hospitals.
13	In response to concerns over the implementation of this
14	policy they delay the enforcement through 2013, which was extended
15	by Congress to 2014.
16	Direct supervision requires that a physician is immediately
17	available when the service is provided. This is difficult in many
18	of these rural settings.
19	Many outpatient services such as continued chemotherapy,
20	administration of IV fluids or drawing of blood can be safely
21	administered under general supervision, a fact that CMS itself
22	recognized in its delay of the policy.
23	Further, small rural hospitals often face staffing and

1	workforce shortages that make direct supervision of these
2	services incredibly difficult.
3	There are a lot of challenges facing our rural hospitals,
4	as you know all too well, Congresswoman Jenkins. This
5	legislation, I think, would go some distance to remedying at least
6	one of those issues facing them and I thank you for introducing
7	this legislation. I am happy to be a part of it, and I yield back.
8	Thank you.
9	Mr. Pitts. Chair thanks the gentleman and now recognizes
10	the vice chair of the subcommittee, Mr. Guthrie, 5 minutes for
11	an opening statement.
12	Mr. Guthrie. Thank you.
13	Thank you, Mr. Chairman, and I appreciate my classmate from
14	the 2008 class coming in, being here with us this morning, Ms.
15	Jenkins.
16	But thank you, and I appreciate you holding this hearing on
17	the number of important bills. Today, the committee is examining
18	two bills that I introduced H.R. 1361, the Medicaid Home
19	Improvement Act, and H.R. 1362, the Medicaid Reports Act.
20	These are both good government bills that help strengthen
21	the Medicaid program and protect valuable taxpayer dollars. H.R.
22	1361, the Medicaid Home Improvement Act, caps the maximum
23	allowable equity for beneficiaries to qualify for long-term care

1	under Medicaid.
2	Currently, in some states those with home equities not
3	home values but home equities above \$828,000 can qualify for
4	Medicaid assistance. My bill reindexes the maximum threshold of
5	\$500,000, adjusted for inflation.
6	With an average home sale in the United States at \$221,000,
7	the current limits allow those not truly in need to access Medicaid
8	dollars, draining federal and state dollars.
9	H.R. 1362, the Medicaid REPORTS Act, requires states to
10	submit an annual report that identifies the sources and amounts
11	of funds used by the state to finance the nonfederal share of
12	Medicaid.
13	With the growing burden the Medicaid program is placing on
14	the federal budget and those of each of our states, it is important
15	that we know how states are coming up with the dollars necessary
16	to meet their Medicaid match.
17	Again, Mr. Chairman, I appreciate you holding this hearing
18	to examine these and other important issues and I look forward
19	to talking more with our witnesses and yield back the balance of
20	my time.
21	Anybody seeking time? I yield back.
22	Mr. Pitts. Chair thanks the gentleman.
23	As usual, all written opening statements of the committee

will be made part of the record and we will proceed to our first panel.

On our first panel today we have the Honorable Lynn Jenkins,

Second District of Kansas, and we thank you for coming to talk about your legislation.

You may proceed.

1	STATEMENT OF THE HON. LYNN JENKINS, A REPRESENTATIVE IN CONGRESS
2	FROM THE STATE OF KANSAS
3	
4	Ms. Jenkins. Chairman Pitts, Ranking Member Green,
5	honourable members of the committee, thank you for holding this
6	hearing and inviting me to speak on H.R. 2878, a critical piece
7	of legislation.
8	The bill would delay Medicare's physician direct supervision
9	requirement for outpatient therapeutic services in critical
10	access and small rural hospitals until 2016.
11	In January of 2014, the Centers for Medicaid and Medicare
12	Services began enforcing a requirement that physicians must
13	supervise outpatient therapy at critical access hospitals and
14	other small rural hospitals.
15	CMS' decision meant that routine outpatient procedures such
16	as drawing blood or undergoing active therapy would have to be
17	directly supervised by a physician.
18	This decision by CMS would have put a severe strain on
19	providers, particularly those in rural areas, while providing no
20	quality improvements for the patients they serve.
21	Most of these outpatient procedures are relatively simple,
22	are very safe and would not benefit from a federal mandate that
23	that physician always be in the room, and as a practical matter

1	in rural hospitals across Kansas such a requirement is simply not
2	feasible.
3	I was proud to introduce legislation last Congress that
4	delayed this Medicare direct supervision requirement through 2014
5	and it was signed into law with bipartisan support.
6	It has been widely recognized as an effective tool to improve
7	care in rural hospitals and keep the regulatory burden in check.
8	Unfortunately, rural hospitals are once again staring down
9	the threat of this federal mandate from CMS. The existing law
10	delayed enforcement action from CMS has expired.
11	Accordingly, I have now reintroduced similar legislation
12	this Congress, further delaying enforcement until 2016. It is
13	about this legislation, H.R. 2878, which this committee has
14	graciously invited me to speak today.
15	When I think about the health care needs facing my district,
16	there is nothing more challenging than ensuring access to quality
17	and accessible rural health care.
18	Rural America is struggling and the 84 critical access
19	hospital in Kansas are the lifeblood of our rural communities.
20	The presence of facilities such as a critical access hospital
21	in a community could be the deciding factor in whether or not the
22	next generations of children decide to raise their family in their

home town or perhaps whether or not a business decides to locate

1	there.
2	Easy access to emergency care can be a life and death
3	situation and we cannot threaten the existence of these facilities
4	by piling on the regulatory burden from Washington.
5	Earlier this year I invited the CEO of Holton Community
6	Hospital to testify about this issue before the Ways and Means
7	Committee Subcommittee on Health.
8	Holton Community Hospital happens to be responsible for
9	serving my hometown, Holton, a community of just over 3,000
10	Kansans.
11	She explained in great detail that direct supervision would
12	be extremely burdensome, costly and is simply unrealistic at a
13	hospital serving rural America. The result of enforcing this
14	mandate would be to severely limit the type of services rural
15	health care hospitals could offer and it would threaten their
16	financial stability at a complicated and uncertain time in our
17	nation's health care system.
18	H.R. 2878 will correct this problem. It will do so by
19	reinstating the moratorium on enforcement of this unnecessary
20	regulation. It has broad bipartisan support in Congress and the
21	support of key stakeholders including the American Hospital
22	Association, the National Rural Health Association and the Kansas

23

Hospital Association.

1	As a small town girl, I feel strongly that folks in rural
2	communities deserve access to quality health care. I can't
3	emphasize enough that rural hospitals rural communities in
4	Kansas and across the country depend on access hospitals like
5	critical access hospitals which are directly threatened by CMS's
6	action.
7	I hope the members from both parties can come together once
8	again to ensure high quality and timely care is available to you
9	no matter where you live in America. Companion legislation was
10	introduced by Senators Thune, Moran and Jon Tester.
11	It has passed the Senate back in September. I also want to
12	thank my lead cosponsor on the legislation, Congressman Dave
13	Loebsack and for all his hard work and advocacy on the issue as
14	well.
15	I urge my colleagues to support the legislation and move it
16	forward in a timely fashion.
17	Thank you all for allowing me to join you today.
18	[The statement of Ms. Jenkins follows:]
19	
20	****** INSERT 1 *******

1 Mr. Pitts. Chair thanks the gentlelady. Really appreciate 2 you taking time out of your busy schedule to come and present 3 testimony to us today. As usual, we will not have any questions for our members 4 5 presenting testimony. So we will excuse the gentlelady with our 6 thanks and call our second panel to the witness table. And while 7 they are setting up the table I would like to submit the following document for EC request for the record. It is a statement from 8 9 the American College of Obstetricians and Gynecologists. Without objection, so ordered. I will introduce our second 10 11 panel in the order they will testify. First, Ms. Katherine Iritani, director of the Health Care Government Accountability 12 13 Office, and then Ms. Anne Schwartz, Ph.D., executive director, 14 Medicaid and CHIP Payment and Access Commission. 15 Thank you very much for coming today. Your written 16 testimony will be made a part of the record. You will each be 17 given five minutes to summarize your testimony. 18 So with that, Ms. Iritani, you are recognized for 5 minutes.

1	STATEMENTS OF KATHERINE IRITANI, DIRECTOR, HEALTH CARE TEAM, GAO;
2	ANNE SCHWARTZ, PH.D., EXECUTIVE DIRECTOR, MEDICAID AND CHIP
3	PAYMENT AND ACCESS COMMISSION
4	
5	STATEMENT OF KATHERINE IRITANI
6	Ms. Iritani. Chairman Pitts, Ranking Member Green and
7	members of the subcommittee, thank you for this opportunity to
8	be here today as you consider ways to strengthen the jointly
9	financed federal and state Medicaid program, now the largest
10	health care program in the nation by enrollment.
11	My testimony today will cover a body of GAO work from recent
12	years on two complex topics federal oversight of certain large
13	payments states often make known as supplemental payments and how
14	states finance the nonfederal share of their programs.
15	Supplemental payments are above and beyond regular payment
16	rates for services and states have considerable flexibility for
17	making them. States can distribute them to only a small number
18	of providers, often hospitals.
19	Congress and CMS have taken important steps to enhance
20	Medicaid program integrity through better oversight of these
21	payments. We believe there are opportunities for even more
22	improvements.
23	Our recent work on certain Medicaid supplemental payments

1	that states often make has shown that better federal information
2	is needed to understand and oversee them.
3	The payments have been growing in size and now total over
4	\$20 billion a year and can amount to tens or hundreds of millions
5	a year to a single provider.
6	CMS and others need better information to understand whose
7	states are paying, how much they are paying and how such payments
8	relate to services provided to Medicaid beneficiaries.
9	Many states have made supplemental payments that greatly
10	exceed the provider's cost of providing Medicaid care. In 2012,
11	we found that 39 states had made supplemental payments to over
12	500 hospitals that resulted in total Medicaid payments exceeding
13	the hospitals' cost of providing Medicaid care by \$2.7 billion.
14	Payments are not limited to costs under Medicaid but payments
15	that greatly exceed costs may not be economical and efficient as
16	required by law.
17	Now, let me turn to our work on state financing, which has
18	concluded that better information on state sources of funds to
19	finance Medicaid is also needed. States are allowed within
20	certain limits to seek funds from providers and local governments
21	to fund Medicaid payments.
22	States can, for example, tax providers or seek
23	intergovernmental fund transfers from local governments to help

1 finance the nonfederal share. 2 We have found that states are increasingly depending on local 3 governments and providers for financing, which can ultimately shift Medicaid costs not only to providers and local governments 4 5 but to the federal government. 6 On the basis of our national survey of state Medicaid 7 programs, in 2012 about \$46 billion or 26 percent of the nonfederal share of Medicaid was financed with funds from providers and local 8 9 governments, a 21 percent increase from 2008. Taxes on health care providers almost doubled in size during 10 11 that time from \$9.7 to \$18.7 billion. Such taxes are subject to 12 certain restrictions, for example, to ensure that taxes are broad 13 based and uniform. 14 Cost shifts to the federal government can occur through financing arrangements that concentrate financing of the payments 15 16 on those providers who receive the payments. 17 For example, a state can increase payments for Medicaid providers such as hospitals, impose a tax on those providers for 18 the nonfederal share and draw down federal matching funds for the 19 20 payments. 21 CMS and other stakeholders are not well positioned to assess 2.2 payments states make to individual institutional providers. 23 Federal data on certain supplemental payments states often make

1	is not complete, reliable, uniform or accessible.
2	CMS has important initiatives underway but CMS has reported
3	that legislation is needed to compel states to report such
4	payments uniformly and to subject them to audit.
5	CMS also lacks good data on state financing sources. Such
6	data are needed to ensure financing is appropriate and to
7	understand how payments affect beneficiary access to care.
8	In conclusion, a needed step towards strengthening the
9	Medicaid program is to make payments and financing more
10	transparent.
11	For this large and growing program, CMS and others need to
12	know whose states paying and in what amounts and right now CMS
13	lacks sufficient data to know this.
14	We have suggested that Congress consider requiring CMS to
15	require states to report not at these payments. We have also
16	recommended that CMS develop a strategy for improving information
17	on state sources of funds for Medicaid.
18	In view of growing costs in enrollments, such transparency
19	can help ensure the program is efficiency and effectively meeting
20	the promise of providing medical assistance to our nation's
21	low-income populations.
22	Mr. Chairman, this concludes my testimony. I am happy to
23	answer any questions.

- 1 Mr. Pitts. Chair thanks the gentlelady and now recognizes
- 2 Ms. Schwartz 5 minutes for her opening statement.

1	STATEMENT OF ANNE SCHWARTZ
2	
3	Ms. Schwartz. Good morning, Chairman Pitts, Ranking Member
4	Green and members of the Subcommittee on Health.
5	I am Anne Schwartz, executive director of MACPAC, the
6	Medicaid and CHIP Payment and Access Commission.
7	As you know, MACPAC is a congressional advisory body charged
8	with analyzing and reviewing Medicaid and CHIP policies and making
9	recommendations to Congress, the secretary of HHS and the states
10	on issues affecting these programs.
11	Its members, led by Chair Diane Rowland and Vice Chair Marsha
12	Gold, are appointed by GAO and the insights I will share this
13	morning reflect the consensus views of the commission itself
14	anchored in a body of analytic work conducted over the past five
15	years and we appreciate the opportunity to share our views this
16	morning.
17	My comments today will focus on reporting of provider level
18	data on non-DSH supplemental payments and contributions to the
19	nonfederal share, the subject of two bills being considered by
20	the subcommittee H.R. 2151 and H.R. 1362.
21	The commission shares the objective of transparency
22	reflected in these two bills. There are several compelling
23	reasons that providers' specific data should be reported. First,

these data are necessary for assessing whether state payments and

rates are consistent with federal statute. 2 3 While states have considerable flexibility in setting rates and payment methods, Section 1902(a)(30)(a) of the Social 4 5 Security Act requires that Medicaid payments be consistent with 6 efficiency, economy, quality and access and that they safequard 7 against unnecessary utilization. 8 But information on the base Medicaid payments that providers 9 receive that is the per case or per diem payment associated with the delivery of specific services to specific Medicaid 10 11 beneficiaries provides only a partial picture of how much Medicaid 12 is paying a given provider. 13 To assess payment fully, policy makers need to know the 14 amount of Medicaid payment that providers receive including both 15 claims-based and supplemental payments less the amount that 16 providers contribute towards the nonfederal share of Medicaid 17 expenditures. 18 The level of payment can be considered the most basic measure 19 of economy and is essential to an assessment of patient 20 efficiency. A measure of value that compares what is being spent -- economy -- to what is obtained -- quality, access, use of 21 2.2 specific services. 23 Typically, an analysis if whether a health care payment is

economical includes comparison to the cost to provide a given

2 service and in comparison to what other payers pay for a comparable 3 service in a given geographic area. Other health care payers including Medicare commonly conduct 4 5 In Medicaid, however, federal policy makers such assessments. 6 and program administrators do not have complete data to make such 7 assessments and therefore to ensure that payments are consistent with the delivery of quality necessary care to beneficiaries. 8 9 The second reason for collecting provider level data is that Medicaid spending for supplemental payments is substantial and 10 11 growing. In fiscal year 2014, states reported making \$24.2 billion 12 13 in non-DSH supplemental payments to hospitals, more than 20 14 percent of total Medicaid fee for service payments to hospitals 15 nationally and more than 50 percent in some states. 16 The amount of funds raised through providers and local 17 government contributions is also significant and increasing. 18 As such, the federal government has a reasonable expectation 19 of having complete payment and financing data that permit it to 20 understand and oversee states' use of Medicaid funds. In light of these concerns, in March 2014 MACPAC recommended 21 2.2 that the secretary of HHS collect and report data on non-DSH 23 supplemental payments at the provider level and just last week

1 in deliberations on a report on disproportionate share hospital 2 payments that is due to Congress on February 1st, the commission 3 voted unanimously on a recommendation focused on reporting of data for both payments and the nonfederal share. 4 5 Specifically, MACPAC recommends that the secretary collect 6 and report hospital-specific data on all types of Medicaid 7 payments for all hospitals that receive them. 8 In addition, the commission recommends that the secretary 9 collect and report data on the sources of nonfederal share necessary to determine net Medicaid payment at the provider level. 10 11 Efforts to fully understand provider payment levels are more 12 relevant now than at any time in the program's history. Use of 13 supplemental payments is growing, particularly to hospitals 14 through Section 1115 expenditure authority. 15 In addition, interest and payment reforms that incentivize 16 greater value in the delivery of health service is also growing. 17 Even so, lack of solid data on net payments makes it extremely difficult to assess the effectiveness of these efforts. 18 MACPAC shares this subcommittee's interest in ensuring that 19 20 taxpayer dollars are spent appropriately on delivery quality necessary care and preventing and reducing fraud, waste and abuse. 21 2.2 Provider level data on supplemental payments and

contributions to the nonfederal share would provide greater

1	transparency and facilitate Medicaid payment analysis including
2	assessments of Medicaid payment adequacy and analysis of the
3	relationship between payment and desired program objectives.
4	Again, thank you for this opportunity to share MACPAC's work
5	with the subcommittee and I am happy to answer any questions.
6	
7	[The statement of Ms. Schwartz follows:]
8	
9	****** INSERT 3 ******

1	Mr. Pitts. The chair thanks the gentlelady both of the
2	witnesses for your testimony. I will begin the questioning and
3	recognize myself 5 minutes for that purpose.
4	This is for both of you. We will start with you, Ms. Iritani.
5	What data does CMS currently collect about the sources of the
6	nonfederal share Medicaid funding?
7	Ms. Iritani. CMS collects some data on the sources of funds
8	on a case by case basis. When states submit a new request for
9	approval for a state plan, CMS asks several questions about the
10	sources of funds.
11	It is not very accessible this data and it is not in
12	a uniform manner. CMS also collects some data on provider taxes.
13	But CMS acknowledges that the data are unreliable and incomplete.
14	Mr. Pitts. Anything to add, Ms. Schwartz? Let me ask you,
15	what additional data do you think they need and how will having
16	this data improve CMS's ability to oversee states' financing of
17	Medicaid? Both of you.
18	Ms. Iritani. Additional data that CMS needs includes data
19	on all sources of funds used to finance the Medicaid program.
20	Currently, CMS does not collect this data.
21	In order to understand net payments to providers, as Ms.
22	Schwartz has discussed the need for understanding, we need to
23	understand whether or not the financing of payments is being

1 concentrated on certain providers that also receive payments and 2 in order to understand this we need to collect complete data on 3 how states finance the nonfederal share of payments. Ms. Pitts. Ms. Schwartz, do you want to add anything? 4 5 Ms. Schwartz. Just to add that our primary concern in 6 conducting this analysis is to get provider-specific data on their 7 contributions to the nonfederal share, which would allow us then 8 to net those contributions out from the total payments that they 9 are receiving Medicaid to get a true picture of what they are being 10 paid. 11 Ms. Pitts. Okay. 12 Now, Ms. Iritani, in your written testimony you indicate that 13 HHS acknowledged that additional data was needed to ensure that 14 states comply with federal requirements regarding how much local 15 governments may contribute to nonfederal share. 16 But despite this, HHS has said that no further action is 17 Can you explain these seemingly contradictory 18 statements, explain why GAO believes that additional data is 19 necessary to properly oversee the program? 20 Ms. Iritani. Yes. We made a recommendation to CMS that they collect -- develop a strategy for collecting better 21 2.2 information and I think CMS disagreed because they did not believe 23 that information on the sources of Medicaid financing was needed

1	on a payment specific basis.
2	They collect information in the aggregate but they don't
3	collect information that would enable us to ascertain how much
4	individual providers are collecting, as Ms. Schwartz discussed
5	a need for.
6	Mr. Pitts. Now, what does the required reporting and
7	auditing of DSH payments tell us about the utility of requiring
8	similar reporting and auditing for non-DSH supplemental payments?
9	Ms. Iritani. The DSH payments are subject to complete
10	reporting of both the financing of the payments and this the
11	information for non-DSH payments is lacking.
12	And I am sorry, could you repeat the question?
13	Mr. Pitts. Yes. What does the required reporting and
14	auditing of DSH payments tell us about the utility of requiring
15	similar reporting and auditing for non-DSH supplemental payments?
16	Ms. Iritani. Right. So the required reporting and
17	auditing of DSH payments has been very important for understanding
18	the who the payments are going to and at what levels and the
19	non-DSH payments are currently not subject to similar
20	requirements.
21	Mr. Pitts. Okay.
22	Ms. Iritani. We have suggested that non-DSH payments really
23	need to be comparable to the DSH payments in terms of the extent

1	of the reporting.
2	Currently, one cannot tell with the non-DSH payments the net
3	payments that providers are actually receiving because you cannot
4	tell on a provider specific basis what a provider is actually
5	contributing to the financing of a particular payment.
6	So the financing of a payment could be, for example, 100
7	percent concentrated on the providers who receive the payments.
8	Therefore, you know, the net payments that the providers receive
9	is actually much lower.
10	Mr. Pitts. My time is expired. The chair recognizes the
11	ranking member of the subcommittee, Mr. Green, 5 minutes for
12	questions.
13	Mr. Green. Thank you, Mr. Chairman, and I would like to ask
14	the panel to provide information on how Medicaid payments work.
15	I think Medicaid payments are so complicated. Even as I was a
16	state legislator in Texas it was tough.
17	I know that we would appreciate a little more information
18	about how this actually works. Ms. Schwartz, given that the issue
19	of rate setting is so complicated, explain how states set these
20	rates and what types of payments are provided to providers and
21	what is recorded to CMS.
22	Ms. Schwartz. Yes. Setting payment rates and
23	methodologies is one of the parts of the Medicaid program that

2 Hospitals -- pay hospitals in very different ways. 3 them use a system similar to the prospective payment system in Medicare where they make a per case payment at the diagnosis level 4 5 for a number of different services that are provided in the 6 hospital. 7 Some states still pay hospitals per diem. The range is all 8 over the place in both how they pay, the special adjustors they 9 have for that and the actual payment rate. We have collected some of this information from MACPAC and it is a rather unwieldy 10 11 spreadsheet that gives you a sense of the complexity of those 12 payments. 13 One of the things that MACPAC is most interested in is trying 14 to get a sense of how payments can be used to leverage proper 15 appropriate greater value care and as part of that we need to be 16 able to know both the methods and the payment rates and to be able 17 to net out these additional payments. 18 So it is quite complex with considerable state flexibility 19 reflecting historical practices and the local markets. 20 Mr. Green. Okay. Ms. Iritani, my understanding is it is 21 very hard to gather Medicaid data and indeed to compare Medicaid 2.2 data, given the time lag on availability of that data and how 23 different all these programs are from one another.

1

varies the most.

1	Is that a problem that you encounter regularly in your work
2	at the GAO?
3	Ms. Iritani. Regular payment data is available to us. But
4	the supplemental payments that states often make are not reported
5	in the claims data that go to the CMS.
6	So states really have all the data that shows who those
7	payments are going to and so that is part of the transparency that
8	we believe is needed is more data at the federal level on whose
9	supplemental payments are going to and for what purposes and in
10	what amounts.
11	Mr. Green. Ms. Schwartz, I thought your point about linking
12	other sources of data to better understand a full picture of the
13	payments was interesting.
14	Can you expand on that recommendation?
15	Ms. Schwartz. Well, as Ms. Iritani says, claims are
16	available and are reported up to the federal level. So we know
17	on a per case or per diem level what hospitals are making.
18	Supplemental payments are not paid associated with claims
19	and what is reported by the states to the federal level is the
20	aggregate amount across all institutions in a particular class
21	and we can't associate that big chunk of dollars that is being
22	reported to the particular institutions that receive them.

States, clearly, know this information because they are

1	making the payments. But states also have many different data
2	systems and approaches to making those payments and so you can't
3	just go out and ask every state report this information and get
4	the right answer.
5	So that is the desire to have the secretary specify a method
6	by which those data would be reported so that they could be
7	consistently reported and available to analyze both at the
8	national level and across states.
9	Mr. Green. Okay. Both Ms. Iritani, both you and Ms.
10	Schwartz mentioned that CMS is actually taking quite a number of
11	steps on the issue and I am glad the administration is taking those
12	steps in recent years to shed light on.
13	I know there has been a GAO recommendation through
14	administrations on both sides of the aisle. Can you talk about
15	CMS work on nonsupplemental payments in recent years?
16	Wasn't that work based in part on longstanding GAO
17	recommendations and isn't it true that CMS hasn't even finished
18	rolling out the new actions on the supplemental payments?
19	Ms. Iritani. Yes. CMS has taken some significant steps,
20	we would agree, to try to improve the transparency and
21	accountability of supplemental payments.
22	Recently, CMS has, for example, had initiatives to try to
23	require states to submit reports that would provide information

1	on the financing and payments for supplemental payments.
2	This information is more than what they have had before. It
3	is extensive. CMS has provided that information to a contractor
4	to assess how they can use it to improve oversight, for example.
5	CMS also has a initiative known as T-MSIS, Transform Medicaid
6	Information System reforms to try to collect better information
7	on claims. That would include supplemental payments.
8	Mr. Green. Okay.
9	Thank you, Mr. Chairman. I yield back.
10	Mr. Pitts. Chair thanks the gentleman.
11	I recognize the vice chair of subcommittee, Mr. Guthrie, 5
12	minutes for questions.
13	Mr. Guthrie. Thank you, Mr. Chairman, and my questions to
14	Ms. Iritani will be directed at you, and I know you have talked
15	about some of the things I am going to ask you about but I would
16	like to give you a chance to elaborate with through the question
17	I am going to move forward.
18	So in your testimony you point out that states generally use
19	general revenue funds for their Medicaid share but you point out
20	that states can use other financing options, specifically that
21	states are increasingly relying on providers and local
22	governments to finance their Medicaid share.
23	Can you discuss some of the ways states are financing their

1	Medicaid share? It is not just general revenue?
2	Ms. Iritani. What we have reported on are apart from the
3	general revenues, which is the majority of how states finance,
4	are is the growing reliance on taxes on health care providers,
5	for example, to help finance the nonfederal share of payments.
6	Intergovernmental transfers, which can be used between units of
7	government to
8	Mr. Guthrie. Can you give an example of one an example?
9	Ms. Iritani. So, for example, a local government may
10	operate a hospital and an intergovernmental fund transfer might
11	be a transfer from the local government to the state that it is
12	in to provide the nonfederal share of a payment that is going to
13	the provider.
14	And other method is known as certified public expenditures,
15	which is basically certifying that an expenditure was made for
16	Medicaid. That can also be used as a nonfederal share.
17	Mr. Guthrie. Okay. And I think every member of this
18	committee wants to ensure that vulnerable beneficiaries are
19	protected and receive the Medicaid benefits, which are eligible.
20	But I know many of us also want to ensure that federal
21	Medicaid policy doesn't unnecessarily crowd out private sector's
22	role.
23	Medicaid long-term care is the largest chunk of Medicaid

1	spending and represents one of the biggest challenges to the
2	program's sustainability over the long term.
3	My bill, H.R. 1361, the Medicaid Home Improvement Act, seeks
4	to address the concerns of GAO in this area and requires states
5	to submit an annual report identifying the sources and amounts
6	of funds used to as the Medicaid report items are use funds
7	to finance their nonfederal share of Medicaid.
8	Can you talk about how that will be beneficial as we move
9	forward?
10	Ms. Iritani. Yes. Currently CMS does not collect data on
11	the sources of funds that states use for Medicaid and there are
12	several reasons why we believe that information is needed.
13	One is just to enforce Medicaid requirements on limits that
14	are set on the extent that states can rely on providers and local
15	governments.
16	There is a limit that states cannot it is called the $60/40$
17	rule that states can only obtain a certain proportion of funds
18	from local governments and providers.
19	The other is just to understand net payments that providers
20	actually receive. Without having better data on the extend that
21	payments are being financed by the providers who receive the
22	payments, we can't really understand net payments to providers.
23	Mr. Guthrie. Okay. Also a bill I have today is the Medicaid

1	Home Act that changes the equity requirement to \$500,000 plus
2	I mean, plus inflation.
3	Can you talk about if this policy were adopted how
4	individuals could access the equity interest in their home through
5	a variety of legal means such as reverse mortgages, home equity
6	loan or other financial vehicles?
7	Ms. Iritani. I am not prepared to answer that question but
8	I would be happy to get information for you for a question for
9	the record.
10	Mr. Guthrie. Okay. All right.
11	And can you talk about there is an exception under current
12	law which my bill does not change which allows an individual with
13	any level of home equity to qualify for Medicaid if an individual
14	spouse, child under 21 or child that is considered blind or
15	disabled also live in the home? Are you familiar with that
16	provision?
17	Is that maybe, Ms. Schwartz, you have a checking in
18	on that do you have a
19	Ms. Schwartz. Yes, that is correct.
20	Mr. Guthrie. That is correct. Okay.
21	And given that there are few seconds here given the
22	aging of the Baby Boomers and the growth of long-term care, have
23	MACPAC or GAO conducted any analysis about the challenges

1	unrestrained growth in this part of the program imposes on federal
2	and state budgets?
3	For example, CBO estimates that federal spending alone on
4	Medicaid long-term care will be \$77 billion this year. So is GAO
5	or MACPAC looking at the long-term care and ensuing Baby Boomer
6	arrival, not just at retirement but also older in life so that
7	more demands on long-term care?
8	Ms. Iritani. We have several engagements underway around
9	long-term care and Medicaid.
10	Mr. Guthrie. Thanks.
11	Ms. Schwartz. Yes, and MACPAC is engaged in a long-term work
12	plan on analyzing spending trends and different aspects of the
13	Medicaid program and we are just beginning that work, and since
14	long-term care is such a significant part of the program it will
15	be included as part of that area of work.
16	Mr. Guthrie. Thank you. My time is expired and I yield
17	back.
18	Mr. Pitts. Chair thanks the gentleman.
19	I now recognize the ranking member of the full committee,
20	Mr. Pallone, 5 minutes for questions.
21	Mr. Pallone. Thank you, Mr. Chairman.
22	I want to follow up on my colleague's discussion of long-term
23	care.

1	Dr. Schwartz, I would like to discuss how the proposed
2	Medicaid Home Improvement Act would affect beneficiary
3	eligibility for long-term care services.
4	As you know, the Medicaid program is the backbone of our
5	country's long-term care system. Sadly, even with Medicaid as
6	the safety net, the majority of Americans lack the options or
7	resources to sufficiently plan for future long-term care needs.
8	And, you know, my questions relate to, obviously, to the
9	spend down provision, which I think is a terrible way to pay for
10	long-term care actually shameful, in my opinion.
11	The last thing I want to do is to take someone's home to pay
12	for their long-term care. Could you briefly describe the purpose
13	of the home equity exemption?
14	Ms. Schwartz. I think there is two purposes. One is to
15	allow living family members to remain in the home while the
16	beneficiary is in an institution and the other is to there is
17	the limit that exists on there to ensure that the government is
18	seeing a contribution of assets to their care. So that is the
19	purpose of the act.
20	Mr. Pallone. Thank you.
21	And states are allowed the option of maintaining a higher
22	home equity threshold. What is the purpose of allowing states
23	to choose between different equity allowances?

1	I know for New Jersey, you know, in our state it is much
2	higher. We have chosen the option of the higher equity.
3	Ms. Schwartz. Well, I am not an expert in this area and it
4	is not an area where MACPAC has done any significant work.
5	But in general, states exercise flexibility in definitions
6	within the program to reflect local circumstances in their
7	communities and I do believe New York and New Jersey are two of
8	the states that have allowed a higher exemption, presumably
9	reflecting the higher market value of real estate in those areas.
10	Mr. Pallone. I mean, that is absolutely the case. I mean,
11	it is not unusual at all for, you know, a person of average income,
12	you know, to be living in a home that is worth \$800,000, which
13	I think would qualify in New Jersey under the higher because
14	New Jersey has opted for the higher equity but might not but
15	I think wouldn't qualify if this bill became law because they
16	wouldn't allow states to have a higher threshold.
17	Would you expect the Medicaid Home Improvement Act to have
18	different effects in different states because it wouldn't allow
19	this higher threshold?
20	Ms. Schwartz. Well, certainly, to the extent that states
21	have a higher threshold now would affect those states more than
22	those who have a threshold similar to what is in the bill.
23	Mr. Pallone. Thank you.

I mean, my concern, Mr. Chairman, you know, I find this 1 2 proposed piece of legislation to be very concerning with regard 3 to this home equity threshold and not allowing states to raise the threshold. 4 5 I mean, our country, we know, has still not implemented a 6 thoughtful comprehensive approach to long-term care yet this bill 7 would only serve to restrict eligibility to long-term services and supports and I would -- you know, I can't stress enough that 8 9 in states, you know, like New Jersey where, you know, real estate -- you know, you have this much higher ability -- it costs a lot 10 11 more, essentially, to have a home in New Jersey. And I -- I mean, the last thing I would want to see is people to have to, you know, 12 13 sell their home because the threshold is reduced. 14 Let me ask you, Dr. Schwartz, I understand that Medicaid and 15 CHIP have experience in quality performance measures through the 16 Pediatric Quality Measures Program and this program was 17 established in 2009 with the goal of improving the quality of care delivered to our nation's pediatric patients. 18 19 Could you briefly describe the Pediatric Quality Measures 20 Program and the effect it has had in advancing pediatric care for 21 Medicaid patients? I think you have a minute. 2.2 Ms. Schwartz. Sure. 23 The core set of measures, as you mentioned, was developed

1 in 2009 and all states are reporting at least two of the measures. 2 The median is 14 measures, and there are things like the share 3 of kids between the ages of 3 and 17 with an outpatient visit to a primary care practitioner, the share of children up to the age 4 5 of 2 are up to date on their vaccines, share of births at low birth 6 weight. These are areas that are agreed have a clinical definition 8 as being meaningful from the purposes of high quality care. 9 MACPAC has commented on the importance of improving the 10 number of states reporting those measures and increasing the 11 number of measures and also strengthening the capacity of CMS to calculate those measures for states from claims data to the extent 12 13 that it is possible. 14 Mr. Pallone. Do you have any suggestions for improvement? 15 I know my time is almost up but if you had to mention one or two. 16 Ms. Schwartz. To the extent that data from claims that 17 states submit up to CMS that those data can be used and that require 18 no additional data collection on the part of the states that would 19 be a really valuable way to get more information on the performance of different states in providing quality pediatric care. 20 21 Mr. Pallone. Thank you. 2.2 Thank you, Mr. Chairman. 23 Mr. Pitts. The chair thanks the gentleman and now

1 recognizes the gentleman from Illinois, Mr. Shimkus, five minutes 2 for questions. 3 Thank you, Mr. Chairman. And welcome back, Mr. Shimkus. it is good to see you. This question would be for both of you 4 5 as I begin. Many of us are familiar with the Disproportionate 6 Share Hospitals, or DSH, supplemental payments. However, can you 7 please explain what non-DSH supplemental payments are, who they 8 go to and what purpose they serve? Ms. Iritani, why don't you 9 start? 10 Ms. Iritani. Yes, the non-DSH payments are a type of 11 supplemental payments that states often make under the upper 12 payment limit that is established under Medicaid or under Medicaid 13 demonstrations. The purposes are largely unknown, which is part 14 of why we believe there is a need for more reporting so we can 15 understand who these payments are going to and for what purposes. 16 Mr. Shimkus. Ms. Schwartz, do you want to comment on it? 17 Sure. I can just say that the non-DSH Ms. Schwartz. 18 supplemental payments are calculated by a state looking across 19 a class of providers, say, public hospitals, nonprofit hospitals, 20 looking at the total payments under fee-for-service that are paid, and then the difference between that payment amount and what would 21 2.2 have been paid under Medicare principles, which is generally more. 23 So the difference there is the amount that the state can make in

1 non-DSH supplemental payments, and it uses those funds presumably 2 to target different types of hospitals. 3 But again, as Ms. Iritani said, that is one of the reasons we would like to be able to get the provider-specific data to see 4 5 the relationship between the specific payments and which 6 hospitals are receiving them. 7 So in the question previously, Ms. Iritani, Mr. Shimkus. you talked about -- we were talking about general funds payment 8 9 and I think you did raise the issues of taxes. So some states use provider taxes to finance the non-federal share of Medicaid 10 11 cost which has been used to shift cost to the federal government. 12 Can you kind of talk through that? 13 Ms. Iritani. Yes, so to the extent that financing of large 14 payments is concentrated on the same providers receiving those payments, there can be a cost shift. For example, when we looked 15 16 at this issue in a recent report, we looked at certain new 17 arrangements that states put in place where they increased 18 provider payments but they at the same time imposed a tax on those 19 providers, the same providers, to pay for the non-federal share. 20 And so then they drew down the federal matching for that payment, for those payments, and in the end the federal government 21 2.2 paid much more, hundreds more, or tens of millions for those new 23 payments. The providers who received the payments funded the

1	non-federal share and the state ended up not having to pay more
2	for those payments.
3	Mr. Shimkus. Ms. Schwartz, do you want to comment? No.
4	That is fine.
5	And last for Ms. Iritani, GAO has had longstanding
6	recommendation for CMS to require additional reporting and
7	auditing of non-DSH supplemental payments. Why don't you think
8	CMS has implemented those recommendations?
9	Ms. Iritani. CMS has agreed with our findings, but with
10	regard to that particular recommendation they said that they would
11	need to be required to do so; that because of the effect on states
12	that they would need legislation to be ordered and to be able to
13	do that.
14	Mr. Shimkus. Okay, very good. I yield back my time. Thank
15	you, Mr. Chairman.
16	Mr. Pitts. The chair thanks the gentleman. I now recognize
17	the gentle lady from Florida, Ms. Castor, five minutes for
18	questions.
19	Ms. Castor. Great. And that is where I want to pick up.
20	So CMS says that they do not have the authority to go out and
21	collect all of the data from states on their supplemental
22	payments. Do you agree with that, that legislation is needed?
23	Ms. Iritani. We defer to CMS on that. We believe that in

1 the past when CMS has tried to require states to report information 2 that states didn't necessarily want to report or want to report 3 at the level that CMS needed it, CMS needed legislation. Ms. Castor. Ms. Schwartz, do you agree with that? 4 5 Ms. Schwartz. CMS is collecting information from states to 6 demonstrate compliance with the upper payment limit regulations. 7 And for the purposes that MACPAC is interested in, the payments 8 on provider-specific data on the non-DSH supplemental payments 9 from those regulations might be sufficient. We don't have any access to those data. CMS does not share at a lot of details. 10 11 We do know that they have been talking about a regulation 12 on supplemental payments, so it does seem that there is activity 13 going on and that as part of its oversight activity it does have 14 the ability to collect the payment information. I believe an 15 audit is another level in which I think it is probably fair to 16 say that they would need legislation to conduct an audit as they had to do the additional --17 18 Ms. Castor. And it certainly would give them the leverage 19 to say to states we need it to be accessible and we need it to 20 be uniform, because these supplemental payments go to all 50 states, correct? So oftentimes I imagine the data comes back in 21 2.2 different forms. What impact now has Medicaid expansion in some 23 states and not in others had on supplemental payments?

1	Ms. Schwartz. I am not sure that we have done the analysis
2	of the supplemental payments of expansion versus non-expansion
3	states and it is something we could do. In any case, it would
4	still be at the aggregate state level and not give you a picture
5	of what is happening to individual providers.
6	Ms. Castor. How about with the expansion of the 1115 waivers
7	and supplemental payments? Has the trend towards states having
8	those Medicaid waivers changed the format of supplemental
9	payments at all?
10	Ms. Schwartz. Many of those waivers have allowed states to
11	continue making supplemental payments, and so we do know that
12	those payments under the 1115 waivers are increasing.
13	Ms. Castor. So, and in the Medicaid managed care rules that
14	were proposed recently, did those rules propose any type of
15	standardized reporting for supplemental payments through the
16	waivers or
17	Ms. Schwartz. I am not sure if the rules specifically
18	mention that, but in general supplemental payments are not
19	permitted under managed care because in managed care the plan is
20	making a payment to the institution not the state.
21	Ms. Castor. So it is more applicable to the 1115 waivers
22	to states than in managed care rules for sure.
23	Ms. Schwartz. That is my understanding.

In one example, I wonder if GAO has Ms. Castor. Okav. looked at states that have taken supplemental payments and done things with them that really are outside the bounds of the intent of the Medicaid laws. Do you know of any cases where states have said, okay, we are going to provide, use supplemental payments, that revenue, and pay providers that don't serve the Medicaid population? Ms. Iritani. Years ago in prior reports, we have looked at how excessive supplemental payments were used by states and did find that the payment revenues could be used for non-Medicaid purposes. And in more recent years, we have just been looking at the level of the supplemental payments and how that they relate to costs of the providers for providing Medicaid and that is where we have found that many states are making payments that are much Ms. Castor. In Florida we had that crop up where the state went in and said, here, we are going to take some of the supplemental payments and give it to some providers that were not serving the Medicaid population. And that is a real worry in my home county that has a half cent sales tax that they use as an intergovernmental transfer and to bring down their Medicaid match. So I think this is a very good idea for us to standardize

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

the reporting from states and get all the data so we can ensure
the funds are being spent accordingly. Thank you, and I yield
back.
Mr. Pitts. The chair thanks the gentle lady. I now
recognize the gentleman from Missouri, Mr. Long, five minutes for
questions.
Mr. Long. Thank you, Mr. Chairman. And Ms. Iritani, what
factors prompted CMS to require audits and reporting of the DSH
payments?
Ms. Iritani. CMS identified concerns with states making
excessive payments over the limits, and Congress had required them
to also establish reporting and auditing requirements. And some
of our work also found concerns with excessive payments and also
requirements on providers to return the non-federal share to the
state, so effectively reducing the net payments that some
providers received. So CMS did, and now requires DSH payments,
Disproportionate Share payments to be reported on a
facility-specific basis and subject to audit.
Mr. Long. Okay. These overpayments, were they an anomaly,
or do you know what percentage they found, find or think are
overpaid?
Ms. Iritani. Well, what I can say is the original, the very
first DSH audits found that the majority of states, I believe it

was 41, had overpaid at least one hospital. And one of our reports

Τ.	was 41, had overpaid at least one hospital. And one of our reports
2	reported on the findings of the DSH audits and 41 states had paid
3	over 500 hospitals 2.7 million on the non-DSH side, but they also
4	reported on significant noncompliance on the DSH side in terms
5	of
6	Mr. Long. Significant. Do you have any idea what
7	percentage when you said significant?
8	Ms. Iritani. So the DSH payments, payments that were in
9	excess of the hospitals' uncompensated care and/or not calculated
10	with acceptable data and methods, 41 states that made DSH payments
11	exceeded the hospitals'
12	Mr. Long. Yes, but that doesn't tell me what percentage.
13	Ms. Iritani. So 24 percent of the hospitals were found to
14	have received DSH payments that were noncompliant.
15	Mr. Long. Twenty four percent across the board.
16	Ms. Iritani. Twenty four percent of hospitals.
17	Mr. Long. Okay. Okay, thank you. And Dr. Schwartz, on
18	Thursday, MACPAC commissioners recommended that the secretary of
19	HHS should collect and report hospital-specific data on all types
20	of Medicaid payments for all hospitals that receive them. In
21	addition, they said the secretary should collect and report data
22	on the sources of non-federal share necessary to determine net
23	Medicaid payments at the provider level.

1	As I have been told, HHS said legislation was necessary to
2	implement reporting and auditing requirements for DSH payments
3	and that legislation would be needed to implement similar
4	requirements for non-DSH supplemental payments. So why did
5	MACPAC target its recommendations to the secretary?
6	Ms. Schwartz. Sure. We have not asked for nor received a
7	review from CMS of our recommendations, so I don't know what CMS
8	will say about our specific recommendation. MACPAC's
9	recommendation was for reporting of payment information, which
10	we know from what CMS already is asking of states in the UPL payment
11	demonstrations that it is already asking for similar types of
12	information, and that is why we believe that the secretary had
13	the authority to do this. Auditing is a different step, and
14	auditing is a much more intense activity as seen in the DSH audits
15	and that is not what MACPAC was asking for. MACPAC was asking
16	for collecting and reporting payment data, and so we believe that
17	the secretary has the authority to do that.
18	Mr. Long. Okay, thank you. With that I yield back, Mr.
19	Chairman.
20	Mr. Pitts. The chair thanks the gentleman and now
21	recognizes the gentleman from Oregon, Dr. Schrader, five minutes
22	for questions.
23	Mr. Schrader. Thank you, Mr. Chairman. I guess for GAO,

1	have you evaluated what the cost-benefit might be in changing from
2	reporting classes of overpayments versus going to the individual
3	providers?
4	Ms. Iritani. We have evaluated the cost-benefit, but we
5	would note that this is required on the DSH side. So, and non-DSH
6	payments are now higher in amounts than DSH payments, but the
7	non-DSH payments are not subject to reporting and auditing as with
8	DSH.
9	Mr. Schrader. Has there been any consideration of just
10	increasing the Medicaid payments as opposed to going with the DSH
11	and non-DSH supplemental payments that we have got?
12	Ms. Iritani. Well, ideally, Medicaid payments would be
13	sufficient to ensure access in a local area comparable to what
14	others outside of Medicaid would be receiving.
15	Mr. Schrader. Like everyone in this committee and Congress
16	fully realizes, Medicaid payments are not sufficient and as a
17	matter of fact are so low that many providers can't accept Medicaid
18	patients. We have the same problem with Medicare. I think a lot
19	of folks need to be aware that that is a very, very low
20	reimbursement rate compared to the private insurance market.
21	Ms. Iritani. Yes, our work has found that Medicaid payments
22	are lower generally for certain services than private.
23	Mr. Schrader. Has there been any move to just fund Medicaid

to the various states and providers based on outcomes? There has been a lot of talk in health care recently about outcomes, quality based health care. What I can say is that I think that there are Ms. Iritani. some demonstrations that are trying to incentivize outcomes by making payments for that. Mr. Schrader. MACPAC have any comments on that? Ms. Schwartz. I think there is a lot of activity at the state level to try and link payment to outcomes through different approaches such as health homes, bundling of payments, different approaches. We don't know very much yet about the outcomes and whether they have affected outcomes. That is something we would be very interested to know. And it is also very difficult to conduct that research because you have to be able to control for everything else that is going on in the health system and in the patients' lives to be able to attribute the outcomes to specific actions on the part of the beneficiary and the provider. Mr. Schrader. Well that is interesting and that is always true whether it is an education bill or anything we do. But we are doing that right now in Medicare. We are trying to get at that in Medicare. We are doing that under the Affordable Care Act. So I don't think it is impossible, and certainly there could

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

1 be risk based reimbursement to accommodate the types of 2 socioeconomic factors that people have. 3 And I would argue respectfully that rather than us trying to micromanage all the states and the different providers, it 4 5 would be a heck of a lot easier for us, particularly non-doctors, 6 although I guess I am a veterinarian but I wouldn't want to be 7 the guy in charge of your healthcare, that we go to an outcome 8 based reimbursement system where we could easily judge whether 9 or not the people are staying healthier, staying out of the hospitals, getting that quality based healthcare. 10 11 That should really be what we are about, then our task here 12 would be pretty easy. We would just be able to have a common set 13 of outcomes, and your job would be a little bit easier and we could 14 see whether or not things are doing well or not. 15 Another question. In the REPORTS bill why do we have the 16 40/60 rule? Why is that significant? What is the goal of having that rule? 17 18 Ms. Iritani. I can't speak to the legislative history 19 around that rule, but I think that the concept generally is that 20 states should share in the non-federal share of the financing that 21 2.2 Mr. Schrader. Well, why do we specify it can't be more than 23 40 or more than 60? What is the point of that? Who cares? Why

1	do we care? I am the federal government. As long as someone is
2	paying their fair share, why do I care?
3	Ms. Iritani. Well, I think that to make sure that the
4	incentives are for sufficient and economical payments that the
5	state should be sharing in the cost of the payment.
6	Mr. Schrader. Yes, but who cares if it comes from the local
7	government or a private enterprise or the state? Who cares?
8	Ms. Iritani. The concern around the reliance on providers
9	and local governments for financing the non-federal share is when
10	the burden on financing Medicaid rests with, for example, the
11	providers who are serving the beneficiaries. From the providers'
12	standpoint, the payment they receive from Medicaid is the net
13	payment. It is not the full payment, it is the payment less the
14	taxes or other contributions they might be making for the payment
15	that they receive.
16	Mr. Schrader. Mr. Chair, I would just respectfully suggest
17	we are micromanaging and should let the states do what they do
18	best and just regulate the outcomes. I think that would be a
19	smarter proposal. And I yield back. Thank you, sir.
20	Mr. Pitts. The chair thanks the gentleman. I now recognize
21	the gentleman from Indiana, Dr. Bucshon, five minutes for
22	questions.
23	Mr. Bucshon. Thank you, Mr. Chairman. I would agree with

1 what you just said and I think we are micromanaging. And I can 2 tell you why CMS wants to know the information, because they want 3 to decrease payments to the Medicaid program. They want to save And I was a provider before I was a surgeon and you can't 4 5 have access if you continue to decrease Medicaid payments. 6 Because you have a program that needs fundamentally restructured 7 in my view. You can't have both. And so now, states, including Indiana with the Healthy 8 9 Indiana Plan 2.0 which is a HSA based way to manage the Medicaid population, now what basically your testimony is telling me that 10 11 wow, you guys came up with a great system but we don't want you 12 to do it because we are concerned it is going to cost the federal 13 government more money and we are trying to save money here. 14 So the question -- I mean, I am playing a little devil's 15 The question I have is why does the federal advocate here. 16 government care? I mean, for example, Healthy Indiana Plan 2.0 17 uses hospital taxes to, as you probably know, to help fund the 18 expanded state share of the expansion under the Affordable Care 19 Act. 20 Why does that matter to the federal government? Because 21 what they are doing then is they are reimbursing providers at a 2.2 higher level than traditional Medicaid. Guess what that does? 23 It gets the providers to take Medicaid patients so that we get

access so low-income people actually can see a doctor. So why
does that matter to the federal government? Does that cost the
federal government any more money than it would if they did it
in a traditional way?
Ms. Schwartz. I think the most fundamental reason that the
federal government pays is that when you look at the financing
federal, non-federal, the federal government is still paying on
average 57 percent of the cost of the Medicaid program and much
more than that in many states
Mr. Bucshon. So?
Ms. Schwartz notwithstanding how
Mr. Bucshon. So what?
Ms. Schwartz. So the interest is ensuring that that amount
of money is being used consistent with the aims of the statute.
Mr. Bucshon. Okay, so they want to micromanage the Medicaid
program just like Dr. Schrader said. The basic, and what I am
getting is that the reason is, is because the federal government
wants to micromanage the states. I mean that is my view on that
and again I am all for reporting, and I think people, states should
be compliant with coverage and make sure people are getting
adequate coverage.
But other than that, I mean the question I have is why does
it matter to the federal government? That is why I support

1 fundamental Medicaid reform that gives the states a certain amount 2 of money and let them do what they need to do with it versus having 3 all these strings attached. I mean, I think we are just finding today with this hearing why we need to fundamentally restructure 4 5 the Medicaid program, because people are spending literally 6 1,000s of hours trying to figure all this stuff out. 7 Like I said, I don't have a problem with needing to be reporting if it has an impact on patient access. I mean, if there 8 9 is a concern that based on states using local or state funding for the non-federal portion is having an impact on access and 10 people are not getting the services that is one thing. 11 12 just because the federal government wants to say, well, look, we 13 don't have to pay you as much because you have found a way to use 14 local money or state money to help yourself, then I am against 15 that. 16 And so why does it matter if a state reports, for example, 17 in the aggregate versus an individual provider? Why would the 18 federal government care? It is the same amount of money. 19 Ms. Iritani. Well, as you point out, we want to make sure 20 that Medicaid payments are going for Medicaid purposes and then prove access to Medicaid beneficiaries. 21 2.2 Mr. Bucshon. And I agree with that. 23 Ms. Iritani. Without knowing the amount that an individual

provider is contributing to the payment that they are receiving, we can't actually understand whether or not the payment is being used basically for fiscal relief for the state or actually serving to improve access for Medicaid beneficiaries. That is fair enough. But that there what you Mr. Bucshon. just said is making the assumption that states are purposely violating federal law for their own benefit. If you make -- I am just saying that CMS needs to know this because they want to prevent states from purposely violating the law by using Medicaid dollars for non-, for example, giving payments to people who are not providing coverage to Medicaid patients. Is that true or not true? Ms. Iritani. And it is not necessarily even violating the States can make payments and receive federal matching up to the upper payment limit, and there is no limit on Medicaid payments in relation to costs. But this data is really needed to understand the extent that payments are going to providers who are actually financing the non-federal share, therefore reducing the net payments to the providers because --Mr. Bucshon. My time is expired. So again I will just finish by saying who cares? Because it is the same cost to the federal government, who cares? I yield back. 23 Mr. Pitts. The chair thanks the gentleman and now

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

recognizes the gentleman from Maryland, Mr. Sarbanes, five minutes for questions.

Mr. Sarbanes. Thank you, Mr. Chairman. I had a question about -- I am very interested in these demonstration projects to explore alternative venues or settings for long-term care and the financing of those. So I guess the obvious example of experimenting with this is there are some waiver and demonstration programs that have allowed for Medicaid reimbursement for placement in, say, assisted living facilities as opposed to long term in nursing care facilities. I don't know that there has been, but you would know, I imagine, demonstration projects that are reimbursing through Medicaid for placement in somebody's home where they are getting some home care.

But my question is, as those kinds of alternatives are being explored are there also alternative kind of financing structures or formulas being looked at at the same time? So obviously you would be looking at different kinds of reimbursement amounts depending on this setting, but is there any reason, for example, to look at some of these asset thresholds and other things depending on -- my instinct would say no, but I am just wondering, has that kind of analysis accompanied the experimenting of just where you might reimburse for this kind of care?

Ms. Iritani. We have work plan to look at Medicaid payments

2.2

for assisted living. We have not done work looking at financing
of Medicaid payments necessarily directed to long-term care, if
that is your question.
Mr. Sarbanes. Okay. And are there, is it in your bailiwick
to tell me whether there are demonstrations that are actually
looking at Medicaid reimbursement for home care where somebody
is actually staying in the home?
Ms. Iritani. There are, increasingly, states moving from
a fee-for-service type of payment for long-term care services to
managed care which would be a capitated payment amount to cover
all services including long-term care.
Mr. Sarbanes. So in that instance there would be a capitated
payment for providing care along a continuum that could include
some component of home care along with institutional care; is that
what you are saying?
Ms. Iritani. Correct.
Mr. Sarbanes. Okay. All right, thank you. I yield back.
Ms. Schwartz. I can just add to that that about half of
payments for long-term services supports in Medicaid are now
occurring in a non-institutional setting, and this reflects a very
big shift over the past 20 years when it was primarily in
institutional settings. And that is primarily through 1915(c)
waivers that have allowed states to move, allow folks to stay in

1 their own homes and receive services if that is something that 2 is valuable to them. 3 And there have also been grants under the money follows the person program to help states transition people from nursing homes 4 5 to homes settings or to allow people to stay in their homes and 6 not end up in a nursing facility. Mr. Sarbanes. Thank you. Mr. Pitts. The gentleman yields back. The chair now 8 9 recognizes the gentleman from Maryland, Mr. Bilirakis, five minutes for questions. 10 11 Mr. Bilirakis. Florida. 12 Mr. Pitts. I mean Florida, sorry. 13 Mr. Bilirakis. That is okay. No problem. Well, I have a 14 couple questions here, but I wanted to say how much, with the 15 moving the patient from a long-term care facility to the home, 16 obviously quality of life is number one, but are we saving money 17 at the same time? 18 Those waivers require a demonstration of Ms. Schwartz. 19 savings and so yes. And in the managed long-term services and 20 supports area, I think that is also an area to increase the 21 predictability of the amount that is being spent on long-term 2.2 services and supports. So fiscal concerns are obviously a part 23 of both of those efforts.

1	Mr. Bilirakis. Very good, thank you. A couple more
2	questions, Ms. Iritani and Ms. Schwartz. In your testimony you
3	talk a lot about non-state sources being used to fund Medicaid.
4	Can you explain what these non-state sources are such as provider
5	taxes and how they fund state Medicaid programs?
6	Ms. Iritani. States are allowed to use up to certain sources
7	of funds apart from state general revenues to finance Medicaid.
8	Provider taxes are an increasing method that states use to fund
9	Medicaid which would be a broad-based uniform tax on health care
10	providers, and it could be Medicaid providers to fund Medicaid.
11	And our governmental transfers and certified public
12	expenditures are other methods that are increasingly used to
13	finance the non-federal share of Medicaid. These would be
14	methods that local governments or a local government provider such
15	as county hospitals might use to, for example, in the case of
16	certified public expenditures, to certify that they had expended
17	a certain amount on Medicaid for purposes of getting federal
18	matching for the payment or the fund.
19	Mr. Bilirakis. Do you have anything else to add, please?
20	Ms. Schwartz. No, I don't have anything else to add to that.
21	Mr. Bilirakis. Okay, all right. Okay, federal law
22	requires that provider taxes must be broad based and uniformly
23	imposed and must not hold the providers harmless and cannot

1 provide a direct or indirect quarantee those providers will 2 receive all or part of the tax payment back. How does the 3 use of non-state funding sources such as provider taxes reconcile with federal law? 4 5 Ms. Schwartz. It is permissible under federal law, and 6 changes have been made over time to clarify the circumstances 7 under which it is possible and the ones you just named are examples of that. But it is a permissible activity. There is no 8 9 intimation that something shady is going on with these taxes and they are clearly important in many states as a source of funds 10 11 to support the Medicaid program. 12 Mr. Bilirakis. Okay, next question. Ms. Iritani, in 2014 13 you asked CMS to ensure states report accurate and complete information on all sources of funds used to finance the 14 15 non-federal share of Medicaid. What data did you want to capture 16 and what was CMS's response to your recommendations? 17 Ms. Iritani. Yes, we suggested that CMS come up with a data strategy for obtaining complete and reliable information on 18 sources of funds. Currently CMS does not collect specific 19 20 sources of funding. CMS agreed that they needed better data for oversight purposes, but disagreed with our suggestion that they 21 needed this data at the provider level for in particular 2.2 23 institutional providers.

We felt like the data is needed at the institutional level 1 2 so that a net payment to the provider could be understood. For 3 example, if a hospital is getting 200 million from CMS in a supplemental payment that CMS would also know that that provider 4 5 was being asked to finance a non-federal share, a hundred million 6 or more, whatever the non-federal share of the payment would be. 7 This is important not only for understanding the trends in 8 financing and the net impact on the provider and whether it would 9 be helpful to understand the extent the payments are actually going to improve access to the beneficiaries as opposed to cost 10 11 shifting to the federal government or providing fiscal relief to 12 the states. 13 Mr. Bilirakis. So one final question, if I may, Mr. 14 Chairman. 15 Mr. Pitts. You may proceed. 16 Mr. Bilirakis. Okay, thank you. Ms. Iritani, Medicaid is 17 listed by GAO as a high risk program. Can you explain why this 18 program is listed as high risk? Ms. Iritani. Yes. There are multiple contributing reasons 19 20 based on our body of work over the last years, but Medicaid is 21 a significant program in terms of size, in terms of the number 2.2 of enrollees now, the largest health care program in the country. 23 It is a diverse program. The federal-state nature of it makes

it very difficult for oversight. Our work has identified concerns with gaps in oversight including the transparency of supplemental payments and many other types of issues that contributed to our putting Medicaid on our high risk list. Mr. Bilirakis. Thank you. Thank you very much. I vield back. Mr. Pitts. The chair thanks the gentleman and now recognizes the gentleman from New York, Mr. Collins, five minutes for questions. Thank you, Mr. Chairman. And I want to thank Mr. Collins. our panel for being here. I think examining Medicaid programs are very important and we have kind of been doing it many ways today. I quess I would like to start by standing with Dr. Bucshon in saying if we could block grant Medicaid back to the states I don't even think there would be a need for today's hearing. unfortunately we haven't done that so that is one of the reasons we are having this hearing, which I think is timely. And maybe to respond a little bit to Mr. Guthrie's comments earlier, Medicaid is all over the place when it comes to how states administer them. And maybe to sum up a little bit, I am from New York, which New York with 20 million Americans spends as much on Medicaid as California and Texas combined with 60 million people. That shows you how crazy this program is. Thirty six or so states,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

as I understand it, absorb the Medicaid cost at the state level and there is no local share. It is about 36 out of 50.

Well, the 14 states of which New York is certainly one, pushed this back to the county level. In the case of Erie County where I am from, Buffalo, I was the county executive, and 100 percent of our property tax did not even cover our Medicaid share at the county level; 100-plus percent of our county tax covered Medicaid, which meant the county had to live on sales tax.

Well, when it gets to DSH it is worse. In New York State, when the federal government makes a DSH payment the state pays nothing. They force 100 percent of the match for DSH payments down to the local level for the county. Eric County, Eric County Medical Center, we are talking about \$40 million in a year.

Now under the ACA, to speak to the folks on the other side that was, the DSH payments were supposed to be reduced dramatically by the expansion of Medicaid and Affordable Care. Well, it hasn't happened. As I understand it now just maybe we will see a DSH reduction in 2018, but that may go the same way as SGR and just kicked down the road. And I just bring this up to put into context how Medicaid is all over the place through the country, and if you are living in Erie County, New York, it doesn't get much worse when it comes to what we are having to bear for that burden.

2.2

ally
from
n in
have
ting
ates
ents
all
to,
d it
hing
Н
appy
d be
h on
beg
one

state to the other? And it would beg the question, why is one state doing one thing and another doing something else, but without the audits how do we know? There are great variations among states in how Ms. Iritani. they finance their programs and the extent of supplemental payments. Mr. Collins. And just from a common sense standpoint it doesn't make any sense to me. So I would certainly urge all my colleagues to support that bill, H.R. 2151, which is simply trying to gather data in a way that would help us all better understand state by state even what is going on. So again, Mr. Chairman, thank you for holding this hearing, and I yield back the balance of my time. Mr. Pitts. The chair thanks the gentleman. Ms. Schwartz, did you want to add anything to that? Ms. Schwartz. Well, I have some data here that show that nationally supplemental payments as a share of inpatient and outpatient hospital payment is about 44 percent, and in New York it is 36.8 percent so it is below the national average. But the figures go all over the place from two percent to there is several states in the 80s and one or two in the 90s. So you are slightly below the average, but like all things Medicaid it varies by state. Mr. Collins. And I think again we could use some data to

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

understand why that variation would be what it is. Thank you very
much.

Mr. Pitts. The chair thanks the gentleman and now
recognizes Mr. Griffith for five minutes.

Mr. Griffith. Thank you very much, Mr. Chairman. As we have discussed in some of the prior testimony, the state may impose a broad based health care tax on providers and use the revenue raised from that tax to pay for the Medicaid program. Virginia looked at that a couple of decades ago and it was rejected because it was considered a sick tax or a bed tax and why would we want to put more burden on those people who are already sick by having a broad based tax on folks who are in the hospital?

But because of the way the FMAP works, the Federal Medicaid Assistance Percentage, the effect of this is that a state can draw down more and more federal spending in its Medicaid program.

Currently these provider taxes are permissible, as we talked about earlier, if they are applied at a rate that produces revenues less than or equal to six percent of the provider's net patient revenues.

Now I know, Ms. Schwartz, you said that is not cheating, but from a Virginia perspective even though it is legal it seems a little bit dicey that you get more money because you charge your sick people more taxes, therefore you can get more money drawn down from the federal government.

2.2

Can you talk about any work that either MACPAC or GAO has done to explore provider taxes to see how they are utilized by the states and how they drive up the spending or how provider taxes can create what we believe in Virginia is a perverse incentive in Medicaid? Either of you all want to tackle that one? Ms. Schwartz. We have written about provider taxes and described the statute as you have and we have expressed, there has been an expression of interest in learning more. But it is a topic that is difficult to study because you are having to look at the finances of the entire state and their tax structure. it is not one that we have a lot to offer now, but I am hopeful that in the future we will have more information to be able to share on that. Mr. Griffith. Well, as Mr. Bucshon said earlier, maybe we would be better off if we just decided what was the right amount for each state and sent it back to them, and then you don't have all these little games being played about we are going to charge our people a sick tax so that we can then draw down more money. I have introduced a bill, the Medicaid Tax Fairness Act, which is co-sponsored by some of my colleagues on the committee, Blackburn, Bucshon and Guthrie. It doesn't get to the whole problem, but it does reduce the current provider tax threshold from 6 percent to 5.5 percent which is what it was just a few years

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

ago. What do you all think of that concept? And there is a follow-up question too.

Ms. Iritani. We have looked at provider, states' uses of provider taxes at a broad level, at a national level, and have found that states are increasingly relying on provider taxes as a source of the non-federal share of Medicaid. And we looked in three states at arrangements where indeed there was an increase in the Medicaid payments and some sort of contribution, for example, through provider taxes from the same providers that were receiving payments.

And so we would agree that there needs to be much more transparency on what is reported. And with regard to your proposal about reducing the provider tax that I would just note that there have been several bodies including CMS in its budget that have also suggested reducing provider taxes as a way to improve the fiscal integrity of Medicaid.

Mr. Griffith. Yes, my bill is actually the first step, I think, but it is H.R. 1400 and then we can go forward from there. And what is interesting is, as folks on the other side of the aisle will recognize, is oftentimes I am in conflict with the Administration. But in December 2010, President Obama's fiscal commission said Congress and the President should eliminate state gaming of Medicaid tax gimmick. They recommended restricting and

2.2

eventually eliminating this practice.

2.2

While this policy would obviously need to be phased in incrementally, does GAO or MACPAC, and I think you have already answered it in part, but do either of you have a position on that policy, and if not can you comment on benefits of reducing the use of the provider taxes over time? And you may have already answered it in your previous answer and I recognize that but did want to get it out there that this is a bipartisan thought. It is not something that we own just on the Republican side or just on the Democrat side. But gaming the system moves money around but it doesn't really help the sick folk. Comments? Agree, disagree?

Ms. Schwartz. I would just say that from the Commission's perspective that interest at the moment has been on transparency and you need those data to be able to then evaluate different policy options. The Commission as of this time has no position on that.

Mr. Griffith. And I would just say at some point, and I haven't introduced a bill and maybe I should, but at some point we need to look at helping folks out. I had a little concept when I was in the state legislature in Virginia that would allow folks who needed medical care maybe not as intense as a nursing home, but needed at least two things a day that were of assistance, and

1	we passed a law that North Carolina has a similar law that
2	would allow a medical cottage to be placed, a temporary to be
3	placed in a family member's backyard, side yard, whatever, worked
4	under the regular laws but it created a zoning exemption for that.
5	It might be a way that we can save money for folks all the
6	way around because it is cheaper than a nursing home but the person
7	is still getting care and they are with their family. I
8	appreciate it, Mr. Chairman. I appreciate the time, and I yield
9	back.
10	Mr. Pitts. The chair thanks the gentleman, and that
11	concludes the questions of the members present. As usual,
12	members who are in other hearings on our committee may have
13	questions who will submit those too in writing along with any
14	follow-up questions. We ask that you please respond promptly.
15	And I remind members that they have ten business days to submit
16	questions for the record, so members should submit their questions
17	by the close of business on Tuesday, November 17th.
18	Very interesting hearing examining various Medicaid
19	programs, a very complex issue. Thank you very much for your time
20	and testimony today. Without objection, the subcommittee is
21	adjourned.
22	[The Bill H.R. 2878 follows:]

1 ********* INSERT 4 *******

1 [Whereupon, at 11:54 a.m., the subcommittee was adjourned.]